Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence.

Volkow ND, Chang L, Wang GJ, Fowler JS, Franceschi D, Sedler M, Gatley SJ, Miller E, Hitzemann R, Ding YS, Logan J.

J Neurosci. 2001 Dec 1;21(23):9414-8.

2.

Partial recovery of brain metabolism in methamphetamine abusers after protracted abstinence.

Wang GJ, Volkow ND, Chang L, Miller E, Sedler M, Hitzemann R, Zhu W, Logan J, Ma Y, Fowler JS.

Am J Psychiatry. 2004 Feb;161(2):242-8.

PMID:
14754772
3.

Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers.

Volkow ND, Chang L, Wang GJ, Fowler JS, Leonido-Yee M, Franceschi D, Sedler MJ, Gatley SJ, Hitzemann R, Ding YS, Logan J, Wong C, Miller EN.

Am J Psychiatry. 2001 Mar;158(3):377-82.

PMID:
11229977
4.

Recovery of dopamine transporters with methamphetamine detoxification is not linked to changes in dopamine release.

Volkow ND, Wang GJ, Smith L, Fowler JS, Telang F, Logan J, Tomasi D.

Neuroimage. 2015 Nov 1;121:20-8. doi: 10.1016/j.neuroimage.2015.07.035. Epub 2015 Jul 21.

PMID:
26208874
5.

Ontogeny of neurokinin-1 receptor mediation of methamphetamine neurotoxicity in the striatum of the mouse brain.

Yu J, Allison S, Ibrahim D, Cadet JL, Angulo JA.

Ann N Y Acad Sci. 2002 Jun;965:247-53.

PMID:
12105100
6.

Methamphetamine-induced loss of striatal dopamine innervation in BDNF heterozygote mice does not further reduce D3 receptor concentrations.

Joyce JN, Renish L, Osredkar T, Walro JM, Kucera J, Dluzen DE.

Synapse. 2004 Apr;52(1):11-9.

PMID:
14755628
7.

Preclinical evaluation of GBR12909 decanoate as a long-acting medication for methamphetamine dependence.

Baumann MH, Phillips JM, Ayestas MA, Ali SF, Rice KC, Rothman RB.

Ann N Y Acad Sci. 2002 Jun;965:92-108.

PMID:
12105088
8.

PET imaging of dopamine transporter and drug craving during methadone maintenance treatment and after prolonged abstinence in heroin users.

Shi J, Zhao LY, Copersino ML, Fang YX, Chen Y, Tian J, Deng Y, Shuai Y, Jin J, Lu L.

Eur J Pharmacol. 2008 Jan 28;579(1-3):160-6. Epub 2007 Oct 10.

PMID:
17977528
10.

Decreased dopamine activity predicts relapse in methamphetamine abusers.

Wang GJ, Smith L, Volkow ND, Telang F, Logan J, Tomasi D, Wong CT, Hoffman W, Jayne M, Alia-Klein N, Thanos P, Fowler JS.

Mol Psychiatry. 2012 Sep;17(9):918-25. doi: 10.1038/mp.2011.86. Epub 2011 Jul 12.

11.

Substance P and cholecystokinin regulate neurochemical responses to cocaine and methamphetamine in the striatum.

Loonam TM, Noailles PA, Yu J, Zhu JP, Angulo JA.

Life Sci. 2003 Jun 27;73(6):727-39. Review.

PMID:
12801594
12.

Prolonged exposure of rats to intravenous methamphetamine: behavioral and neurochemical characterization.

Segal DS, Kuczenski R, O'Neil ML, Melega WP, Cho AK.

Psychopharmacology (Berl). 2005 Jul;180(3):501-12. Epub 2005 Mar 15.

PMID:
15959831
13.

Methamphetamine increases dopamine transporter higher molecular weight complex formation via a dopamine- and hyperthermia-associated mechanism.

Baucum AJ 2nd, Rau KS, Riddle EL, Hanson GR, Fleckenstein AE.

J Neurosci. 2004 Mar 31;24(13):3436-43.

14.

Methamphetamine-induced alterations in monoamine transport: implications for neurotoxicity, neuroprotection and treatment.

Volz TJ, Fleckenstein AE, Hanson GR.

Addiction. 2007 Apr;102 Suppl 1:44-8. Review.

PMID:
17493052
15.

Differential psychostimulant-induced activation of neural circuits in dopamine transporter knockout and wild type mice.

Trinh JV, Nehrenberg DL, Jacobsen JP, Caron MG, Wetsel WC.

Neuroscience. 2003;118(2):297-310.

PMID:
12699766
16.

Different glial response to methamphetamine- and methylenedioxymethamphetamine-induced neurotoxicity.

Pubill D, Canudas AM, Pallàs M, Camins A, Camarasa J, Escubedo E.

Naunyn Schmiedebergs Arch Pharmacol. 2003 May;367(5):490-9. Epub 2003 Apr 9.

PMID:
12684743
17.

Repeated amphetamine treatment causes a persistent elevation of glial fibrillary acidic protein in the caudate-putamen.

Armstrong V, Reichel CM, Doti JF, Crawford CA, McDougall SA.

Eur J Pharmacol. 2004 Mar 19;488(1-3):111-5.

PMID:
15044042
18.

Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers.

Johanson CE, Frey KA, Lundahl LH, Keenan P, Lockhart N, Roll J, Galloway GP, Koeppe RA, Kilbourn MR, Robbins T, Schuster CR.

Psychopharmacology (Berl). 2006 Apr;185(3):327-38. Epub 2006 Mar 3. Erratum in: Psychopharmacology (Berl). 2006 Jul;186(4):620.

19.

Positron emission tomography of striatal serotonin transporters in Parkinson disease.

Kerenyi L, Ricaurte GA, Schretlen DJ, McCann U, Varga J, Mathews WB, Ravert HT, Dannals RF, Hilton J, Wong DF, Szabo Z.

Arch Neurol. 2003 Sep;60(9):1223-9.

PMID:
12975287
20.

The methamphetamine experience: a NIDA partnership.

Hanson GR, Rau KS, Fleckenstein AE.

Neuropharmacology. 2004;47 Suppl 1:92-100. Review.

PMID:
15464128

Supplemental Content

Support Center